<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1011">
  <stage>Registered</stage>
  <submitdate>19/01/2006</submitdate>
  <approvaldate>20/01/2006</approvaldate>
  <actrnumber>ACTRN12606000031561</actrnumber>
  <trial_identification>
    <studytitle>C FEN 0205</studytitle>
    <scientifictitle>a randomised, double-blind, placebo-controlled study assessing the effect of fenofibrate, coenzyme Q10 and their co-administration on ventricular disatolic function in patients with type 2 diabetes</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 diabetes with left ventricular diastolic dysfunction (LVDD)</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>fenofibrate 80mg + CoEnz Q10 100mg
fenofibrate 80mg + CoEnz Q10 200mg
fenofibrate 160mg + CoEnz Q10 100mg
fenofibrate 160mg + CoEnz Q10 200mg
fenofibrate 160mg
CoEnz Q10 200mg

6 MONTHS INTERVENTION</interventions>
    <comparator>Placebo</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>E to E' ratio on cardioechocardiography</outcome>
      <timepoint>Evaluation performed at the end of the 6 months period of treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Classification of patients according to the severity of LVDD.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Type 2 diabetes patients with LVDD and LV ejection fraction equal or greater than 50%.</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>79</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Serum creatinine above 130 micromol/l, ALT/AST above 2xULN, CK above 3xULN.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Decoding enveloppes</concealment>
    <sequence>The random allocation was generated by computer and restricted by blocks. After randomisation, treatments were allocated to the patients following order of randomisation.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/06/2003</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>125</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Fournier Laboratory Ireland</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Ireland</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Fournier Laboratories Ireland</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Patrick Aubonnet</name>
      <address>Laboratoires Fournier SA
Level 1
Building 2
20 Bridge Street
Pymble NSW 2073</address>
      <phone>+61 2 94979727</phone>
      <fax>+61 2 94401382</fax>
      <email>p.aubonnet@au.fournierpharma.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Patrick Aubonnet</name>
      <address>Laboratoires Fournier SA
Level 1
Building 2
20 Bridge Street
Pymble NSW 2073</address>
      <phone>+61 2 94979727</phone>
      <fax>+61 2 94401382</fax>
      <email>p.aubonnet@au.fournierpharma.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>